A series of chemical analogs of sodium houttuynin, the major constituent in the volatile oil of the perennial plant Houttuynia cordata Thunb, were studied for in vitro inhibition of renin activity. At a reaction concentration of 0.196 mg/ml, each of the sodium houttuynin analogs (SHAs), viz., hexanoyl acetal sodium sulfite (SHA-C6), octanoyl acetal sodium sulfite (SHA-C8), decanoyl acetal sodium sulfite (SHA-C10), dodecanoyl acetal sodium sulfite (SHA-C12) and tetradecanoyl acetal sodium sulfite (SHA-C14), inhibited renin activity up to 34.37%, 44.03%, 79.33%, 83.04%, and 93.19% respectively. The IC 50 values (the concentration of SHA that is required to reduce renin activity by 50%) of the most potent analogs were 273, 195, and 44 M for SHA-C10, SHA-C12, and SHA-C14 respectively. Kinetic studies with SHA-14 indicated a linear mixed-type of enzyme inhibition with a K i value of 45.35 M. It was concluded that the SHAs constitute potentially useful ingredients for the formulation of antihypertensive products.
The renin angiotensin system (RAS) plays a key role in the pathophysiology of cardiovascular diseases such as congestive heart failure and hypertension. 1, 2) Renin catalyzes the initial and rate-determining step conversion of angiotensinogen to angiotensin I (Ang I). Angiotensin I is then cleaved by angiotensin converting enzyme (ACE) to release angiotensin II (Ang II), a potent vasoconstrictor that has been identified as a major factor in hypertension. 3, 4) Therefore, inhibition of the RAS is a major target of cardiovascular disease therapies. The main inhibition sites include the rate limiting renin-dependent step, conversion of angiotensin I to angiotensin II, and the active receptor sites for the terminal products of angiotensin II and aldosterone. 5, 6) Inhibition of ACE has been successfully studied and utilized in clinical cardiovascular disorders. 7) However, since ACE is a rather non-selective enzyme that cleaves bradykinin in addition to Ang I, certain side effects seen with ACE inhibitors such as cough or angioneurotic edema might be intrinsically linked to all ACE inhibitors. 8) Moreover, Ang I can also be converted to Ang II by the enzyme chymase, which can reduce the efficacy of ACE-inhibitory agents. Thus inhibitions of the extremely specific enzyme renin or selective Ang II receptor antagonists provide valuable alternative ways to the treatment and prevention of hypertension as compared to ACE inhibition. Renin inhibitors produce a highly selective inhibition of RAS, leading to an improved side-effect profile for therapeutic agents, since renin catalyzes the hydrolysis of only one naturally occurring substrate, angiotensinogen. 9, 10) The renin inhibitors reported so far are mainly peptide analogs (derived from substrate preprorenin), pepstatin and related analogs, phospholipids, and renin antibodies. 11, 12) Poor pharmacokinetic properties, including low oral bioavailability and high clearance, and the high costs of large-scale synthesis have made these agents unattractive as clinical candidates. Thus the search for renin inhibitors has become a formidable challenge, and most programs to date have focused on peptide modification or synthesis. One of the most potent renin inhibitors, Aliskiren, with IC 50 of 0.6 nM, however, is a non-peptidic inhibitor. To the best of our knowledge, there is very scanty information on the renin-inhibitory properties of naturally occurring compounds, especially plant products.
Sodium houttuyfonate analogs (SHAs) are compounds that have a chemical structure similar to that of sodium houttuyfonate, which is derived from the addition of sodium bisulfite to houttuynin. Houttuynin is the major constituent in the volatile oil of Houttuynia cordata Thunb, a wild perennial herb with creeping rootstocks and swollen nodes. 13) Sodium houttuyfonate has been clinically used in antimicrobial medicines for many years in China. 14) Using the molecular structure of sodium houttuyfonate as a starting point, a series of analogs were synthesized by elongation of the hydrocarbon side chain. The analogs were found to have antibacterial, immunological enhancement and lysozyme function modulating activities both in vitro and in vivo [15] [16] [17] [18] but the ability of SHAs to modulate RAS has never been reported. The aim of the present work was to determine the in vitro inhibitory activity and mode of action of SHAs against renin, a potential target for the action of therapeutic agents against cardiovascular disorders.
Materials and Methods
Materials. SHAs (CH 3 -(CH 2 ) n -CO-CH 2 -CH(OH)-SO 3 Na) with 97% purity were synthesized as previously described 19) at the Chemistry Institute of Pharmaceutical Resources, Southwest University, China. Briefly, a carboxylic acid with the appropriate R-chain length was reacted with acetic acid in the presence of calcium hydroxide as catalyst to produce an alkyl ketone, which was then collected by distillation. The alkyl ketone was reacted with sodium bisulfite and ethyl formate at room temperature with constant stirring for 24 h; sodium houttuyfonate analog precipitates were collected by filtration. Finally the crude SHAs were repeatedly crystallized using 50% ethanol until 97% purity was achieved.
14) Pure SHAs were identified using IR Spectra, UV spectrograph, and NMR. The analogs involved in this study are shown in Fig. 1 . Renin (human recombinant), purity ! 99% by SDS-PAGE, was purchased from Cayman Chemical (Ann Arbor, MI). Fluorescent renin peptide substrate 1, Arg-Glu(EDANS)-lle-His-ProPhe-His-Leu-Val-lle-His-Thr-Lys(DABCYL)-Arg, was purchased from Molecular Probes (Carlsbad, CA):
Renin assay. Renin activity was determined as follows using the fluorescence method of Wang et al., 20) with slight modifications: The peptide substrate was diluted to 500 mM with pure dimethyl sulfoxide (DMSO); this stock solution is stable for at least six months when stored desiccated at 4 C and protected from light. For enzyme assay, the substrate stock solution and renin were each diluted to the appropriate concentration using 50 mM Tris-HCl buffer (pH 8.0, containing 100 mM NaCl). The control (uninhibited) reaction mixture contained 20 ml of Tris-HCl buffer, 80 ml of diluted fluorogenic substrate, and 2 ml of diluted renin. The buffer was first mixed with the substrate and incubated at 37 C for 10 min to reach thermal equilibrium. The reaction was then initiated by the addition of renin solution and the time-dependent increase in fluorescence intensity was monitored for 10 min in a Jasco FP-6300 spectrofluorimeter (Japan Spectroscopic Company, Tokyo) equipped with a thermostated microcuvette (100 ml) cell holder that was maintained at 37 C using a circulatory water bath. The following instrument parameters were used to measure fluorescence intensity: excitation wavelength, 340 nm; emission wavelength, 490 nm; excitation bandwidth, 5 nm; and emission bandwidth 10 nm. The initial reaction velocity expressed in arbitrary fluorescence units per min (INT/min), was obtained by least-squares regression analysis of the initial phase of the reaction.
Enzyme inhibition kinetics. SHAs were first dissolved in DMSO and mixed for 30 min at 500 rpm at a temperature of 50 C in an Eppendorf Ò Thermomixer to obtain inhibitor stock solutions. These stock solutions were kept at 4 C and diluted with Tris-HCl buffer before use to give the desired concentrations. Renin activity was assayed as described above, but the 20 ml buffer volume contained various concentrations of inhibitors (SHA-C6, SHA-C8, SHA-C10, SHA-C12, or SHA-C14). The IC 50 value was defined as the concentration of SHA that is required to reduce renin activity by 50%, and was calculated by the non-linear regression method from a plot of SHA concentration versus inhibitory activity. IC 50 was determined only for SHA-C10, SHA-C12, and SHA-C14, because their inhibitory activities were significantly greater (p < 0:05) than those of SHA-C6 or SHA-C8. The type of inhibition was determined from Lineweaver-Burk (L-B) plots using GraphPad version 4.0 (GraphPad Software, San Diego, CA). K m was calculated by the non-linear regression method, while K i was calculated as the Xaxis intercept from a plot of the slopes of the L-B lines against inhibitor concentrations.
Statistical analysis. Each analysis was performed in duplicate, and significant differences (p < 0:05) were determined by the Duncan Multiple Range Test using SAS Version 9.1 (SAS, Cary, NC).
Results and Discussion
Optimal concentrations of renin and substrate for spectrofluorimetric assay
In order to establish enzyme reaction conditions that are suitable for inhibition studies, we determined the optimal concentrations of renin and substrate that would fit the fluorescence assay. This is because of the very high cost of commercial renin, which necessitated the use of minimal amounts of the enzyme. It was also important to establish that the rate of renin activity is dependent on enzyme and substrate concentrations. This is because the fluorometric assay is dependent on instrument settings, which makes it difficult to rely on previously reported enzyme and substrate concentrations. The activities of renin at different enzyme protein concentrations (0.033, 0.05, and 0.1 mg) at a constant substrate concentration (5 mM) are shown in Fig. 2 . The results confirm that the activity of renin was directly proportional to protein concentrations, and the conversion of substrate to product increased with time. Renin activities at a fixed enzyme concentration (0.1 mg) and varying levels of substrate (1.25, 2.5, and 5 mM) are shown in Fig. 3 . The substrate concentrations were chosen because they lie within the range in which the velocity of renin reaction is linear, as previously shown. 21) Our results are consistent with previous reports that have shown direct relationships between enzyme concentration and activity or substrate concentration and activity 20, 21) for the fluorometric assay. Wang et al. 20) also showed that the fluorescence assay is characterized by an initial lag time phase, as was observed in this study.
Renin inhibitory activities of sodium houttuyfonate analogs
Five compounds, SHA-C6, SHA-C8, SHA-C10, SHA-C12, and SHA-C14, each at 0.196 mg/ml, showed different renin inhibitory activities; percentage inhibitions were 34.37%, 44.03%, 79.33%, 83.04% and 93.19%, respectively. The levels of renin inhibition by SHA-C10, SHA-C12, and SHA-C14 were significantly higher (p < 0:05) than the inhibitory levels of SHA-C6 or SHA-C8. Inhibitory activity increased with increases in the length of the aliphatic chain (and molecular weight) of the analogs. These results indicate that the potency of the SHAs is enhanced when aliphatic hydrophobicity is increased. Investigation of the crystal structure of human renin revealed that it is composed of two -sheet domains with a cleft between them. Studies of the conformational structure of the cleft showed that the S3-S1 subsites form a hydrophobic pocket that constitutes a large hydrophobic cavity. 22, 23) It is possible that the inhibitory activity of SHAs is mediated through hydrophobic interaction of the aliphatic carbon chain with the hydrophobic cleft of renin, thereby disrupting the protein conformation that is necessary for optimum enzyme activity. A similar mode of activity has been proposed for aliskrien, an orally active non-peptidic renin inhibitor. 24) Therefore, elongation of the aliphatic chain should promote increased interactions of SHAs with renin, and might be responsible for the higher inhibitory activity of SHA-C14 than of analogs with shorter aliphatic chains. The IC 50 values of SHA-C10, SHA-C12, and SHA-C14 are shown in Table 1 . They confirm that SHA-C14 has the highest potency against renin. The IC 50 values are higher (less potent) than the IC 50 values reported for chemically synthesized compounds that have been evaluated as suitable drug candidates [25] [26] [27] but the results are difficult to compare because previous studies used angiotensinogen as the substrate for inhibition studies, which produces different results from the use of fluorogenic substrates.
Inhibitory kinetics
Lineweaver-Burks plots of renin without and with SHA-C14 (at three concentrations, of 34, 44, and 68 mM), the most potent of the SHAs, are shown in Fig. 4 . The results yielded a K i of 45.35 mM SHA-C14 and a K m value of 6.4 mM; K m increased to 9.58 mM in the presence of the inhibitor, which indicates decreased enzyme activity. The K m value is higher than the 1.5 mM previously reported by Wang et al., 20) which may be a result of differences in the source of renin. The pattern of inhibition was of the mixed-type, which means that SHA-C14 can bind not only competitively with the substrate at the active site but also at other sites (noncompetitive or uncompetitive inhibition) exclusive of the active site of renin. Therefore, SHA-C14 acts as a renin inhibitor by forming enzyme-substrate-inhibitor and enzyme-inhibitor complexes during the reaction to reduce the efficiency of catalysis. As indicated above, it is possible that the binding force is partly due to hydrophobic interactions between the renin hydrophobic cleft and inhibitor through the aliphatic hydrocarbon chain of SHA-C14. Our results are consistent with previous studies that have shown that some compounds also act as mixed inhibitors of renin, 12, 28) though Fig. 3 . Effect of Substrate Concentration on Renin Activity at 37 C. The reaction mixture contained 20 ml buffer, 2 ml of enzyme solution (0.1 mg concentration), and 80 ml of substrate: 1, 1.25 mM substrate; 2, 2.5 mM substrate; 3, 5 mM substrate. Excitation wavelength, 340 nm; emission wavelength, 490 nm; excitation bandwidth, 5 nm; emission bandwidth, 10 nm. The reactions were performed in the absence of inhibitor ( ) or in the presence of 34 ( ), 44 ( ), or 68 mM (Â) of SHA-C14 using 0.1 mg of renin in a total volume of 102 ml. Incubation temperature, 37 C; excitation wavelength, 340 nm; emission wavelength, 490 nm; excitation bandwidth, 5 nm; emission bandwidth, 10 nm. competitive [29] [30] [31] and noncompetitive 32) renin inhibitors have also been reported. The K i value obtained for SHA-C14 in this study is higher than some values (< 17:7 mM) that have been reported for synthetic peptides 12, 25) but the comparison is not easy to make because our study used a synthetic fluorescent substrate while the previous studies utilized angiotensinogen as the renin substrate.
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Conclusions
Due to the very high substrate specificity of renin, it has been very difficult to find suitable inhibitors that can be used as antihypertensive agents. SHAs are already used in traditional Chinese medicines as antimicrobial agents; therefore, there is a high potential for adaptation of them in the formulation of renin-inhibitory products to lower blood pressure. SHAs are low molecular weight compounds that can readily be absorbed into the blood circulatory system to provide physiological benefits. We have found that increases in the aliphatic chain lengths of SHAs are beneficial for increased renin inhibition, probably due to increased hydrophobic interactions between enzyme and inhibitor. The potential for greater renin inhibition can be explored further using SHAs with longer aliphatic chains than those used in this work. Animal experiments are needed to confirm the physiological benefits of the SHAs.
